American Banking and Market News logo

The Latest Headlines at American Banking and Market News

Image about Adobe (NASDAQ:ADBE) Given New $630.00 Price Target at Royal Bank of Canada

Adobe (NASDAQ:ADBE) Given New $630.00 Price Target at Royal Bank of Canada

Adobe (NASDAQ:ADBE – Free Report) had its price target lowered by Royal Bank of Canada from $650.00 to $630.00 in a report released on Friday, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the software... More of this article »
Image about TD Cowen Trims Adobe (NASDAQ:ADBE) Target Price to $640.00

TD Cowen Trims Adobe (NASDAQ:ADBE) Target Price to $640.00

Adobe (NASDAQ:ADBE – Free Report) had its price objective decreased by TD Cowen from $650.00 to $640.00 in a report released on Friday, Benzinga reports. TD Cowen currently has an outperform rating on the software company’s... More of this article »
Image about Adobe (NASDAQ:ADBE) PT Lowered to $640.00

Adobe (NASDAQ:ADBE) PT Lowered to $640.00

Adobe (NASDAQ:ADBE – Free Report) had its target price cut by Bank of America from $700.00 to $640.00 in a research note issued to investors on Friday morning, Benzinga reports. They currently have a buy rating on the software... More of this article »
Image about Ascendis Pharma A/S (NASDAQ:ASND) PT Raised to $260.00 at Wells Fargo & Company

Ascendis Pharma A/S (NASDAQ:ASND) PT Raised to $260.00 at Wells Fargo & Company

Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price increased by Wells Fargo & Company from $196.00 to $260.00 in a research report sent to investors on Friday, Benzinga reports. They currently have an overweight... More of this article »
Image about Lucid Diagnostics (LUCD) Set to Announce Earnings on Tuesday

Lucid Diagnostics (LUCD) Set to Announce Earnings on Tuesday

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) will post its quarterly earnings results before the market opens on Tuesday, March 26th. Individual interested in registering for the company’s earnings conference call... More of this article »
Image about Wayfair Inc. (NYSE:W) Receives Average Recommendation of “Moderate Buy” from Analysts

Wayfair Inc. (NYSE:W) Receives Average Recommendation of “Moderate Buy” from Analysts

Wayfair Inc. (NYSE:W – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. Ten analysts have rated... More of this article »
Image about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twenty-five ratings firms that are presently covering the company, Marketbeat Ratings... More of this article »
Image about Texas Roadhouse, Inc. (NASDAQ:TXRH) Given Consensus Rating of “Moderate Buy” by Analysts

Texas Roadhouse, Inc. (NASDAQ:TXRH) Given Consensus Rating of “Moderate Buy” by Analysts

Texas Roadhouse, Inc. (NASDAQ:TXRH – Get Free Report) has earned an average rating of “Moderate Buy” from the eighteen ratings firms that are currently covering the firm, Marketbeat.com reports. Nine investment analysts... More of this article »
Image about Clarus Co. (NASDAQ:CLAR) Receives Consensus Rating of “Moderate Buy” from Analysts

Clarus Co. (NASDAQ:CLAR) Receives Consensus Rating of “Moderate Buy” from Analysts

Clarus Co. (NASDAQ:CLAR – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Two analysts have... More of this article »
Image about Physicians Realty Trust (NYSE:DOC) Receives Consensus Rating of “Hold” from Brokerages

Physicians Realty Trust (NYSE:DOC) Receives Consensus Rating of “Hold” from Brokerages

Physicians Realty Trust (NYSE:DOC – Get Free Report) has been assigned a consensus recommendation of “Hold” from the nine research firms that are currently covering the company, Marketbeat.com reports. One investment... More of this article »
Image about Booz Allen Hamilton Holding Co. (NYSE:BAH) Receives Consensus Recommendation of “Hold” from Analysts

Booz Allen Hamilton Holding Co. (NYSE:BAH) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Booz Allen Hamilton Holding Co. (NYSE:BAH – Get Free Report) have been given a consensus recommendation of “Hold” by the nine brokerages that are presently covering the firm, MarketBeat reports. One equities... More of this article »
Image about Varonis Systems’ (VRNS) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Varonis Systems’ (VRNS) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Varonis Systems (NASDAQ:VRNS – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. The brokerage currently has a $56.00... More of this article »
Image about UroGen Pharma (NASDAQ:URGN) PT Lowered to $34.00 at Oppenheimer

UroGen Pharma (NASDAQ:URGN) PT Lowered to $34.00 at Oppenheimer

UroGen Pharma (NASDAQ:URGN – Free Report) had its price objective lowered by Oppenheimer from $35.00 to $34.00 in a research report released on Friday, Benzinga reports. The brokerage currently has an outperform rating on the... More of this article »
Image about Stifel Nicolaus Reaffirms Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

Stifel Nicolaus Reaffirms Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

Stifel Nicolaus reissued their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a research note published on Friday, Benzinga reports. The brokerage currently has a $80.00 price target on the biotechnology... More of this article »
Image about Verastem (NASDAQ:VSTM) Rating Reiterated by Royal Bank of Canada

Verastem (NASDAQ:VSTM) Rating Reiterated by Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Verastem (NASDAQ:VSTM – Free Report) in a report published on Friday morning, Benzinga reports. They currently have a $32.00 target price on the biopharmaceutical... More of this article »